Exelixis (NASDAQ: EXEL) reported Q4 EPS of $0.37, $0.13 better than the analyst estimate of $0.24. Revenue for the quarter came in at $228.6 million versus the consensus estimate of $188.76 million.

2019 Financial Guidance

The company is providing the following financial guidance for 2019. Cost of goods sold are expected to be between 4 percent and 5 percent of net product revenues. Research and development (R&D) expenses are expected to be between $285 million and $315 million and includes non-cash expenses related to stock-based compensation of $20 million. Selling, general and administrative (SG&A) expenses are expected to be between $220 million and $240 million and includes non-cash expenses related to stock-based compensation of $35 million. Guidance for the effective tax rate in 2019 is between 21 percent and 23 percent.

For earnings history and earnings-related data on Exelixis (EXEL) click here.